Research programme: TANA inhibitors - ImStar Therapeutics
Latest Information Update: 29 Nov 2013
At a glance
- Originator ImStar Therapeutics
- Mechanism of Action NF-kappa B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia
Most Recent Events
- 29 Nov 2013 Early research in Alzheimer's disease, Amyotrophic lateral sclerosis & Dementia in Canada (unspecified route)